Why Is Jardiance So Expensive? Root Causes Explained

Jardiance is expensive because it belongs to a class of newer diabetes and heart medications that are still under patent protection, and because US law allows drugmakers to set launch prices with little restraint. The list price for a one-month supply sits in the hundreds of dollars, though what people actually pay depends heavily on insurance. There is no single villain here. Several forces stack on top of each other, and understanding them helps you see where your own cost comes from.

Why Is Jardiance So Expensive Compared With Older Diabetes Drugs?

Jardiance is the brand name for empagliflozin. It belongs to a drug class called SGLT2 inhibitors. These drugs work in the kidneys. They block a protein that normally pulls glucose back into the bloodstream, so more sugar leaves the body in urine. That mechanism is different from older drugs like metformin, which mainly reduce how much glucose the liver makes and how well the body responds to insulin.

Metformin has been available for decades. It is generic, and a month’s supply often costs a few dollars. Empagliflozin was approved by the FDA in 2014. Newer drugs carry higher prices for a simple reason: the company that developed them holds exclusive rights to sell them for a set period.

That exclusivity is the core of the story. During the patent term, no other company can sell the same molecule. Without competition, the manufacturer sets the price. When patents expire and generics enter, prices usually fall sharply. That has not happened yet for empagliflozin.

How Do Patents and Market Exclusivity Drive the Price?

A drug patent typically lasts 20 years from the date it is filed. But that clock starts long before a drug reaches pharmacy shelves. Years of laboratory work, animal testing, and human trials happen first. By the time a drug is approved, a meaningful chunk of the patent term is already gone.

To offset that, US law grants additional periods of market exclusivity. These can extend the time when no competitor can sell a generic version. Companies can also file additional patents on things like a drug’s formulation, dosing, or manufacturing process. This practice is sometimes called “evergreening.” It can push back generic competition even further.

The result is a long window with no price competition. During that window, the manufacturer decides what to charge. There is no government body in the US that negotiates the price of most prescription drugs at launch.

What Role Does the US Drug Pricing System Play?

The United States is unusual among wealthy countries. Many others have a national health system that negotiates drug prices directly with manufacturers or sets limits on what it will pay. The US largely does not do this for pharmacy counter drugs. Medicare, the government program for people 65 and older, was historically barred from negotiating most drug prices.

That changed with a law passed in 2022 that allows Medicare to negotiate prices for a limited number of drugs, starting with a small group. Empagliflozin has been named as one of the drugs subject to negotiation in a later round. The negotiated prices are set to take effect in a future year. This is a real shift, but its effect on what any individual pays will depend on their plan and timing.

Because there is no single price setter, list prices in the US tend to run higher than in countries that negotiate. That does not mean everyone pays the list price. It means the starting number is high, and then discounts, rebates, and insurance rules determine the rest.

Why Doesn’t Insurance Always Cover the Full Cost?

Insurance plans often place drugs on tiers. A tier is a category that determines your share of the cost. Newer brand-name drugs usually sit on a higher tier than generics. That means a higher copayment or coinsurance for you.

Plans also use tools like prior authorization. This means your doctor must show the plan that the drug is medically necessary before it will be covered. Some plans require you to try a cheaper drug first. This is called step therapy.

These rules exist because plans are trying to control their own spending. The list price is not what the plan pays. Insurers negotiate rebates and discounts with manufacturers. But those savings do not always reach the person at the pharmacy counter. If your plan uses coinsurance based on the list price, your share can stay high even after the plan gets a discount.

This gap between the list price and the net price is one of the least understood parts of the system. Two people on the same drug can pay very different amounts depending on their plan design.

Are There Programs That Lower the Cost for Patients?

Yes. Several routes exist, though each has limits.

• Manufacturer savings programs. The maker of Jardiance offers a copay card for people with commercial insurance. It can reduce your out-of-pocket cost, but it generally does not apply to people on Medicare or Medicaid.
• Patient assistance programs. These can provide the drug at low or no cost to people who meet income requirements. Eligibility rules vary.
• Insurance formulary alternatives. A different drug in the same SGLT2 inhibitor class, or a different class entirely, may be covered at a lower tier. Whether a swap is appropriate is a medical decision, not a cost decision alone.
• Medicare negotiation. As noted, empagliflozin is among the drugs selected for Medicare price negotiation, with effects arriving in a future year.

It is worth saying plainly: no program removes the cost for everyone. Each one has an eligibility gate.

Is Jardiance Worth the Cost?

That is a clinical question, not a pricing one, and the answer depends on the person. What the evidence shows matters here.

Empagliflozin was studied in a large trial of adults with type 2 diabetes and established heart disease. That trial found a lower risk of death from cardiovascular causes compared with placebo. Another large trial found a lower risk of kidney disease progression in people with chronic kidney disease, with or without diabetes. These are meaningful outcomes, not just changes in a lab number.

This is why the drug is not simply a glucose-lowering pill. It has demonstrated benefits beyond blood sugar in specific groups. That evidence is part of why it holds a place in treatment guidelines for certain patients.

But evidence of benefit in a trial population does not tell you what a drug is worth for any one person. That depends on their conditions, their risks, their other medications, and their finances. Cost is a legitimate part of that conversation, not a distraction from it.

What Can You Actually Do About the Price?

Start by finding out what your specific plan covers. The list price is often not what you pay, and the difference can be large. Call your insurer or check your plan’s drug list.

Ask your prescriber whether a lower-cost option could work for you. Sometimes a generic in a different class is a reasonable substitute. Sometimes it is not, because the heart or kidney benefits are the reason the drug was chosen. Only your clinician can weigh that.

Ask about manufacturer copay cards and patient assistance programs. Ask specifically whether your insurance requires prior authorization or step therapy, since those can delay or block coverage.

One more point worth knowing: the price you see online or at one pharmacy is not the price everywhere. Cash prices, discount cards, and pharmacy-specific deals can vary. It is worth checking more than one source before assuming the number you saw is final.